GENB
Generate Biomedicines, Inc. Common Stock
Nasdaq · usd
Generate Biomedicines, Inc. Common Stock (GENB) trades at $10.52 (+6.91%) as of 6:38:09 AM EST on Nov 19, 2026, -19.53% over the past month. Market cap is $1.34B, with 8.9 days to cover in short interest.
Stock performance
How Generate Biomedicines, Inc. Common Stock (GENB) stock has performed from one day to one year, with its 52-week range.
- 1D
- +5.49%
- 1W
- -23.05%
- 1M
- -19.53%
- YTD
- -17.94%
- 1Y
- -17.94%
- 52-wk range
- $9.68 – $22.67
Key statistics
Today's trading snapshot for GENB: day range, open, previous close, volume and market cap.
- Day range
- $9.68 – $10.54
- Open
- $9.88
- Prev close
- $9.84
- Volume
- 1.05M
- Market cap
- $1.34B
- Shares out
- 129.1M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Generate Biomedicines, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 75.46
- P/B
- 3.52
- P/FCF
- —
- ROE
- -58.8%
- ROA
- -43.4%
- Debt/Equity
- 0.05
- Div yield
- 0.00%
As of Nov 18, 2026
8-K filings
Material corporate events Generate Biomedicines, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Generate Biomedicines, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2026.
- Clinical trial resultsAug 26, 2026
Draft copies of three posters submitted by Generate Biomedicines, Inc. include results of ongoing clinical trials sponsored by the Company, entitled: 'GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients'; 'SOLAIRIA-1 & SOLAIRIA-2: Two Phase 3 randomized, double-blind, placebo-controlled studies of GB-0895, a long-acting anti-TSLP antibody, in severe uncontrolled asthma'; and 'GB-0895, a High-Affinity Anti-TSLP Antibody, Demonstrates Potent and Sustained Pharmacological Activity in Adults with COPD.'
- Charter amendmentMar 2, 2026
The Company filed its amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on March 2, 2026... to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.
GENB short interest
How heavily GENB is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 8.9
- Short interest
- 9.08M
- Avg volume
- 1.02M
As of · reported to FINRA twice monthly.
GENB news
The latest news and headlines about Generate Biomedicines, Inc. Common Stock (GENB).
- 2027 Could Finally Be the Year Cancer Is on the Ropes!positiveGlobeNewswire Inc.· Oct 29, 2026
- Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape CompetitionpositiveGlobeNewswire Inc.· Oct 16, 2026
- Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on MondaypositiveThe Motley Fool· Jul 7, 2026
- Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion MarketpositiveThe Motley Fool· Jun 27, 2026
- A Deep Dive Into Nvidia’s Latest Portfolio MovespositiveInvesting.com· May 20, 2026
Frequently asked questions
What is the Generate Biomedicines, Inc. Common Stock (GENB) stock price today?
Generate Biomedicines, Inc. Common Stock (GENB) is trading at $10.52 (+6.91% on the day) as of 6:38:09 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Generate Biomedicines, Inc. Common Stock?
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug…
What is the short interest in GENB?
As of Oct 30, 2026, GENB has 9.08M shares short and 8.9 days to cover.
What exchange is GENB listed on?
Generate Biomedicines, Inc. Common Stock (GENB) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of GENB with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a GENB analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.